FDA Issues Complete Response Letter for Summit Therapeutics’ Ivonescimab BLA
Summit Therapeutics said the FDA will not approve its ivonescimab application in its current form, citing insufficient evidence of effectiveness without a statistically significant overall survival benefit.
Summit Therapeutics said the FDA will not approve its ivonescimab application in its current form, citing insufficient evidence of effectiveness without a statistically significant overall survival benefit.Key Highlights:Original SEC Filing: Summit Therapeutics Inc. [ SMMT ] - 8-K - Nov. 16, 2026Th…